Full-Time

Accounting Manager

Updated on 5/12/2026

GenBio AI

GenBio AI

51-200 employees

AI-powered biological simulation for drug development

Compensation Overview

$100k - $175k/yr

Palo Alto, CA, USA

In Person

Category
Accounting (1)
Required Skills
Quickbooks
Forecasting
Financial analysis
Requirements
  • Bachelor’s degree in Accounting, Finance, or related field.
  • CPA certification preferred.
  • Minimum of 3 years of accounting experience.
  • Strong understanding of US Generally Accepted Accounting Principles (US GAAP).
  • Experience with international accounting and tax regulations or work with firms that cover international markets, particularly in France and United Arab Emirates.
  • Proficiency in accounting software (e.g., QuickBooks), Google Workspace, and Microsoft Office Suite.
  • Excellent analytical and problem-solving abilities, and strong interpersonal skills.
  • Strong attention to detail and organizational skills.
  • Ability to work independently and as part of a team in a fast-paced environment.
Responsibilities
  • Manage all accounting operations including bookkeeping, accounts payable/receivable, general ledger, expenses, etc.
  • Handle monthly, quarterly, and annual closing processes.
  • Liaise with external accounting firm and tax CPA; oversee tax reporting and compliance for the United States, France, and United Arab Emirates offices.
  • Assist with the consolidation of financial statements for multiple entities.
  • Support the budgeting and forecasting processes.
  • Prepare and analyze financial reports, ensuring accuracy and compliance with US GAAP and IFRS for international operations.
  • Provide financial analysis and support for business decision-making.
  • Ensure compliance with local, state, and federal government reporting requirements and tax filings.
  • Stay updated on industry trends and regulations to ensure compliance and optimal financial practices.
Desired Qualifications
  • Experience with financial consolidation for multiple entities.
  • Good understanding of International Financial Reporting Standards (IFRS).

GenBio AI develops a digital organism called AIDO to simulate biological processes for drug development and personalized medicine. AIDO uses multiscale models to predict how molecules and cells behave, allowing researchers to test millions of potential treatments digitally to find the most effective options. Unlike traditional methods that rely heavily on physical trials, this platform provides actionable insights across multiple biological levels to improve vaccine safety and clinical diagnostics. The company's goal is to accelerate the creation of new medicines and minimize adverse reactions through partnerships with healthcare providers and research institutions.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Palo Alto, California

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 1 AIDO released six foundation models covering 796 species for rapid simulations.
  • Employee count reached 21-50 with $3.7M revenue and $11.8M valuation since 2024.
  • Global offices in California, Paris, and Abu Dhabi expand partnership opportunities.

What critics are saying

  • Insilico's 18 AI drugs in trials, including Phase 3 INS018_055, outpace AIDO in 6-12 months.
  • Recursion's 25 petabytes data and 200+ programs crush GenBio's unvalidated models in 12-18 months.
  • FDA January 2026 guidance mandates Phase 2 validation, halting AIDO adoption in 9-15 months.

What makes GenBio AI unique

  • AIDO simulates millions of treatments using multiscale foundation models from DNA to cells.
  • Dr. Ziv Bar-Joseph leads multiscale model integration for drug discovery since February 2025.
  • Dr. Emma Lundberg drives data strategy as Co-Founder since June 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-7%
PR Newswire
Jun 17th, 2025
Genbio Ai Welcomes Emma Lundberg As Co-Founder And Chief Scientific Advisor

PALO ALTO, Calif., June 17, 2025 /PRNewswire/ -- GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.In this role, Lundberg will focus on the development of GenBio AI's data strategy and other scientific initiatives, advancing its mission to build a generative digital organism

AI Magazine
Jun 17th, 2025
GenBio AI Welcomes Emma Lundberg as Co-Founder and Chief Scientific Advisor

PALO ALTO, Calif., June 17, 2025 /PRNewswire/ - GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.

GenBio AI
May 7th, 2025
How moscot Maps Cells Through Time, Space, and Modality by Dominik Klein

In this talk, Dominik Klein presents "Mapping cells through time and space with moscot" at the Foundation Models for Biology Seminar Series by GenBio AI.

PR Newswire
Feb 28th, 2025
Genbio Ai Expands Global Leadership With Ziv Bar-Joseph As Co-Founder And Chief Scientific Officer

PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited to announce that Dr. Ziv Bar-Joseph has joined as Co-founder and Chief Scientific Officer.In this role, Bar-Joseph will lead work focused on the integration and use of GenBio AI's multiscale foundation models, ensuring they drive real impact in drug discovery, medicine, and beyond. His leadership will be pivotal in helping the company transform AI applications in biology and push the boundaries of biological research.Bar-Joseph brings extensive expertise from Sanofi, a leading global pharmaceutical company. As the VP and Head of R&D Data and Computational Sciences, he led multidisciplinary teams in machine learning, computational biology, and data science to accelerate drug and vaccine discovery. He is also the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU), specializing in biological systems modeling, and AI applications in genomics and systems biology